Srinivasan Beddhu
No Rating Available
(Learn About Our Rating System)

Srinivasan Beddhu, MD

Languages spoken: English, Tamil

Clinical Locations

Primary Location

Veterans Administration Medical Center

500 S Foothill Blvd
Salt Lake City , UT 84148
Get Directions

Dr. Beddhu is a Professor and Dialysis Research Foundation Presidential Endowed Chair in the Department of Internal Medicine. He also serves as the Clinical Research Medical Director in the Department of Internal Medicine. His research focus is on cardiovascular disease, nutritional status and lifestyle factors in CKD and dialysis patients. He leads a strong research team that is conducting studies of large national databases using cutting-edge statistical techniques and investigator initiated randomized controlled trials.

His research is funded by NIH, VA and industry with his current total federal funding exceeding $10 million. He was actively involved for 9 years in the NHLBI-funded Systolic Blood Pressure Intervention Trial (SPRINT) as the Co-Director of the Utah Clinical Center Network (CCN) and the Utah site- PI. He has authored more than 150 publications with many papers in high impact journals. He has mentored junior faculty, post-docs, fellows, residents, graduate students and medical students, some of whom have become independent, funded investigators.

Specialties

Board Certification

American Board of Internal Medicine

Dr. Beddhu is a Professor and Dialysis Research Foundation Presidential Endowed Chair in the Department of Internal Medicine. He also serves as the Clinical Research Medical Director in the Department of Internal Medicine. His research focus is on cardiovascular disease, nutritional status and lifestyle factors in CKD and dialysis patients. He leads a strong research team that is conducting studies of large national databases using cutting-edge statistical techniques and investigator initiated randomized controlled trials.

His research is funded by NIH, VA and industry with his current total federal funding exceeding $10 million. He was actively involved for 9 years in the NHLBI-funded Systolic Blood Pressure Intervention Trial (SPRINT) as the Co-Director of the Utah Clinical Center Network (CCN) and the Utah site- PI. He has authored more than 150 publications with many papers in high impact journals. He has mentored junior faculty, post-docs, fellows, residents, graduate students and medical students, some of whom have become independent, funded investigators.

Board Certification and Academic Information

Academic Departments Population Health Sciences -Adjunct Professor
Internal Medicine -Professor
Academic Divisions Nephrology & Hypertension
Board Certification
American Board of Internal Medicine

Education history

Undergraduate D. B. Higher SEC - School
Professional Medical Medicine - Stanley Medical College M.B.B.S.
Residency Internal Medicine - Stanley Medical College Resident
Residency Internal Medicine - Bangalore Medical College Resident
Residency Internal Medicine - St. Mary's Hospital of Rochester Resident
Fellowship Nephrology - University Health Center of Pittsburgh Fellow
Research Fellow Renal Division - University of Pittsburg Research Fellow

Selected Publications

Journal Article

  1. EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R, EMPA-KIDNEY Collaborative Grou (2025). Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine, 392(8), 777-787.
  2. EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R, EMPA-KIDNEY Collaborative Grou (2025). Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine, 392(8), 777-787.
  3. Rossing P, Birkenfeld AL, Fioretto P, McGill JB, Anker SD, Pitt B, Rohwedder K, Scalise A, Scott C, Filippatos G, FIDELIO-DKD and FIGARO-DKD Investigator (2025). Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis. Clinical journal of the American Society of Nephrology, 20(7), 968-977.
  4. Sarwal A, Boucher RE, Hartsell SE, Wei G, Shen J, Chertow GM, Whelton PK, Cheung AK, McEvoy JW, Greene T, Beddhu (2025). Baseline Diastolic BP and BP-Lowering Effects on Cardiovascular Outcomes and All-Cause Mortality: A Meta-Analysis. Journal of the American Society of Nephrology, 36(5), 911-922.
  5. Shen J, Sarwal A, Singh R, Hartsell SE, Wei G, Nevers M, Christensen JC, Takyi A, Katkam N, Derington CG, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Beddhu (2025). Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes. Diabetes, obesity & metabolism, 27(4), 2120-2130.
  6. Christensen JC, Anand S, Chertow GM, Lyden K, Sarwal A, Bjordahl T, Boucher R, Mohammed A, Oro EG, Akramimoghaddam F, Katkam N, Takyi A, Bissada G, Chakravartula AR, Lee E, Zheng A, Wei G, Greene T, Beddhu (2025). The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney disease. Contemporary clinical trials, 149, 107766.
  7. Zhou J, Williams C, Staplin N, Judge PK, Mayne KJ, Agrawal N, Arimoto R, Green JB, Cherney DZI, Tuttle KR, Leal J, Clarke P, Emberson JR, Preiss D, Wanner C, Landray MJ, Baigent C, Haynes R, Herrington WG, Mihaylova B, EMPA-KIDNEY Collaborative Grou (2025). Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. EClinicalMedicine, 85, 103338.
  8. Sarwal A, Singh R, Wei G, Shen J, Nevers M, Hartsell SE, Derington CG, Takyi A, Chakravartula AR, Katkam N, Boucher RE, Drakos SG, Greene T, Beddhu (2025). Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes. Diabetes, obesity & metabolism,
  9. Brinker L, Sideris K, Wei G, Singh R, Nevers MR, Hartsell SE, Sarwal A, Kyriakopoulos CP, Tseliou E, Benes J, Melenovsky V, Drakos SG, Hanff TC, Carter S, Fang JC, Cho M, Beddhu S, Stehlik (2025). Diabetes Therapy With SGLT2i After Heart Transplant: A Multi-Institutional Analysis. JACC. Heart failure, 13(8), 102520.
  10. Beddhu S, Shiu Y (2025). Muscle Wasting and Arteriovenous Fistula Nonmaturation in Kidney Failure. Journal of the American Society of Nephrology, 36(5), 758-759.
  11. Ikizler TA, Kramer HJ, Beddhu S, Chang AR, Friedman AN, Harhay MN, Jimenez EY, Kistler B, Kukla A, Larson K, Lavenburg LU, Navaneethan SD, Ortiz J, Pereira RI, Sarwer DB, Schauer PR, Zeitler EM, ASN Kidney Health Guidance Workgroup on Obesity and Kidney Disease (2024). ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases. Journal of the American Society of Nephrology, 35(11), 1574-1588.
  12. Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Cheung AK, Maggioni AP, Nangaku M, Rossello X, Tuttle KR, Ihara K, Iwata T, Wanner C, Emberson J, Preiss D, Landray MJ, Baigent C, Haynes R, Herrington WG, EMPA-KIDNEY Collaborative Grou (2024). Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial. Clinical journal of the American Society of Nephrology, 19(9), 1119-1129.
  13. Akbari S, Ten Eyck P, Wendt L, Yamada M, Boucher R, Beddhu S, Jalal D (2024). Trends of Blood Pressure Control in Chronic Kidney Disease Among US Adults: Findings From NHANES 2011 to 2020. Journal of the American Heart Association, 13(20), e034568.
  14. Pajewski NM, Beddhu S, Bress AP, Chang TI, Chertow GM, Cheung AK, Cushman WC, Freedman BI, Greene T, Johnson KC, Jaeger BC, Tamura MK, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Williamson JD, Whelton PK, Wright JT Jr, Drawz PE, Ix J (2024). The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation. Journal of the American Society of Nephrology, 35(12), 1737-1745.
  15. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes (2023). Empagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine, 388(2), 117-127.
  16. Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL, FIDELIO-DKD and FIGARO-DKD Investigator (2023). Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Annals of internal medicine, 176(12), 1606-1616.
  17. Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G, FIDELIO-DKD and FIGARO-DKD Investigator (2023). Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clinical journal of the American Society of Nephrology, 18(5), 602-612.
  18. Gupta A, Boucher R, Wei G, Gronseth G, Parks A, Beddhu (2023). Influence of Baseline Diastolic Blood Pressure on the Effects of Systolic Blood Pressure Lowering on Cognitive Function in Type 2 Diabetes Mellitus. American journal of hypertension, 36(2), 120-125.
  19. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R, FIDELIO-DKD and FIGARO-DKD Investigator (2022). Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes care, 45(12), 2991-2998.
  20. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, FIDELIO-DKD Investigator (2022). Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes care, 45(4), 888-897.
  21. Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan L (2022). Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Obesity (Silver Spring, Md.), 30(12), 2340-2350.
  22. Lyden K, Boucher R, Wei G, Zhou N, Christensen J, Chertow GM, Greene T, Beddhu (2021). Targeting Sedentary Behavior in CKD: A Pilot and Feasibility Randomized Controlled Trial. Clinical journal of the American Society of Nephrology, 16(5), 717-726.
  23. SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius W (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine, 384(20), 1921-1930.
  24. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM, FIGARO-DKD Investigator (2021). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England journal of medicine, 385(24), 2252-2263.
  25. SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius W (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine, 384(20), 1921-1930.
  26. Nasrallah IM, Gaussoin SA, Pomponio R, Dolui S, Erus G, Wright CB, Launer LJ, Detre JA, Wolk DA, Davatzikos C, Williamson JD, Pajewski NM, Bryan RN, SPRINT Research Grou (2021). Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial. JAMA neurology, 78(5), 568-577.
  27. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, Ambrosius W, Chertow GM, Beddhu (2020). The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. Diabetes care, 43(8), 1878-1884.
  28. Chang AR, Kramer H, Wei G, Boucher R, Grams ME, Berlowitz D, Bhatt U, Cohen DL, Drawz P, Punzi H, Freedman BI, Haley W, Hawfield A, Horwitz E, McLouth C, Morisky D, Papademetriou V, Rocco MV, Wall B, Weiner DE, Zias A, Beddhu S, SPRINT Research Grou (2020). Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Post Hoc Analyses from SPRINT. Clinical journal of the American Society of Nephrology, 15(8), 1121-1128.
  29. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G, FIDELIO-DKD Investigator (2020). Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. The New England journal of medicine, 383(23), 2219-2229.
  30. Chang TI, Wei G, Boucher R, Kramer H, Chertow GM, Cheung AK, Greene T, Whelton PK, Beddhu (2020). Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease. Kidney360, 1(5), 368-375.
  31. Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, Beddhu (2020). Sodium Bicarbonate Supplementation and Urinary TGF-ß1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial. Clinical journal of the American Society of Nephrology, 15(2), 200-208.
  32. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene (2019). Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. Journal of the American Society of Nephrology, 30(8), 1523-1533.
  33. Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D, SONAR Committees and Investigator (2019). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet (London, England), 393(10184), 1937-1947.
  34. Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D, SONAR Committees and Investigator (2019). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet (London, England), 393(10184), 1937-1947.
  35. Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B, FIGARO-DKD study investigator (2019). Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American journal of nephrology, 50(5), 345-356.
  36. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G, on behalf of the FIDELIO-DKD study investigators, FIDELIO-DKD study investigator (2019). Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. American journal of nephrology, 50(5), 333-344.
  37. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, Wei G, Campbell RC, Conroy M, Freedman BI, Haley W, Horwitz E, Kitzman D, Lash J, Papademetriou V, Pisoni R, Riessen E, Rosendorff C, Watnick SG, Whittle J, Whelton PK, SPRINT Research Grou (2018). Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation, 137(2), 134-143.
  38. Kramer H, Boucher RE, Leehey D, Fried L, Wei G, Greene T, Rosas SE, Cooper R, Cao G, Beddhu (2018). Increasing Mortality in Adults With Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria. Diabetes care, 41(4), 775-781.
  39. Beddhu S, Greene T, Boucher R, Cushman WC, Wei G, Stoddard G, Ix JH, Chonchol M, Kramer H, Cheung AK, Kimmel PL, Whelton PK, Chertow G (2018). Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. The lancet. Diabetes & endocrinology, 6(7), 555-563.
  40. Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, Cutler J, Fine L, Boucher R, Wei G, Zhang C, Kramer H, Bress AP, Kimmel PL, Oparil S, Lewis CE, Rahman M, Cushman W (2018). Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. Journal of the American Heart Association, 7(18), e009326.
  41. Johnson KC, Whelton PK, Cushman WC, Cutler JA, Evans GW, Snyder JK, Ambrosius WT, Beddhu S, Cheung AK, Fine LJ, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Oparil S, Wright JT Jr, SPRINT Research Grou (2018). Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension (Dallas, Tex., 71(5), 848-857.
  42. Tian M, Tang L, Wu Y, Beddhu S, Huang (2018). Adiponectin attenuates kidney injury and fibrosis in deoxycorticosterone acetate-salt and angiotensin II-induced CKD mice. American journal of physiology. Renal physiology, 315(3), F558-F571.
  43. Beddhu S, Rocco M, Toto R, Craven TE, Greene T, Bhatt U, Cheung AK, Cohen D, Freedman BI, Hawfield AT, Kileen AA, Kimmell PL, LashJ, Papademtriou V, Rahman M, Rastogi A, Servilla K, Townsend RR, Wall B, Whelton PK, SPRINT Rsearch Grou (2017). Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Withour Kidney Disease: A Secondary Analysis of Randomized Trial. Annals of internal medicine, 167(6), 375-383.
  44. Raphael KL, Carroll DJ, Murray J, Greene T, Beddhu (2017). Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease. Journal of the American Society of Nephrology, 28(8), 2483-2490.
  45. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negrón N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE, SPRINT Research Grou (2017). Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine, 377(8), 745-755.
  46. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J, SPRINT Research Grou (2017). Effects of Intensive BP Control in CKD. Journal of the American Society of Nephrology, 28(9), 2812-2823.
  47. Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V, SPRINT Research Grou (2017). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes care, 40(10), 1401-8.
  48. Velasquez MT, Beddhu S, Nobakht E, Rahman M, Raj D (2016). Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time?. Kidney international reports, 1(2), 94-104.
  49. Chen X, Wei G, Jalili T, Metos J, Giri A, Cho ME, Boucher R, Greene T, Beddhu (2015). The Associations of Plant Protein Intake With All-Cause Mortality in CKD. American journal of kidney diseases, 67(3), 423-30.
  50. Beddhu S, Wei G, Marcus RL, Chonchol M, Greene (2015). Light-intensity physical activities and mortality in the United States general population and CKD subpopulation. Clinical journal of the American Society of Nephrology, 10(7), 1145-53.
  51. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius W (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine, 373(22), 2103-16.
  52. Krishnamurthy VM, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, Greene T, Beddhu (2012). High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney international, 81(3), 300-6.
  53. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu (2011). Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney international, 79(2), 228-33.
  54. Raphael KL, Wei G, Baird BC, Greene T, Beddhu (2011). Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney international, 79(3), 356-62.
  55. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu (2009). Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clinical journal of the American Society of Nephrology, 4(10), 1565-74.
  56. Beddhu S, Baird BC, Zitterkoph J, Neilson J, Greene (2009). Physical activity and mortality in chronic kidney disease (NHANES III). Clinical journal of the American Society of Nephrology, 4(12), 1901-6.
  57. Kwan BC, Murtaugh MA, Beddhu (2007). Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. Clinical journal of the American Society of Nephrology, 2(5), 992-8.
  58. Beddhu S, Kimmel PL, Ramkumar N, Cheung A (2005). Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). American journal of kidney diseases, 46(4), 577-86.
  59. Morris D, Samore MH, Pappas LM, Ramkumar N, Beddhu (2005). Nutrition and racial differences in cardiovascular events and survival in elderly dialysis patients. The American journal of medicine, 118(6), 671-5.
  60. Beddhu S, Pappas LM, Ramkumar N, Samore M (2004). Malnutrition and atherosclerosis in dialysis patients. Journal of the American Society of Nephrology, 15(3), 733-42.
  61. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung A (2003). Creatinine production, nutrition, and glomerular filtration rate estimation. Journal of the American Society of Nephrology, 14(4), 1000-5.
  62. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Ramkumar N, Pappas LM, Cheung A (2003). Impact of timing of initiation of dialysis on mortality. Journal of the American Society of Nephrology, 14(9), 2305-12.
  63. Beddhu S, Pappas LM, Ramkumar N, Samore (2003). Effects of body size and body composition on survival in hemodialysis patients. Journal of the American Society of Nephrology, 14(9), 2366-72.
  64. Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson J (2002). Impact of renal failure on the risk of myocardial infarction and death. Kidney international, 62(5), 1776-83.
  65. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel M (2000). A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. The American journal of medicine, 108(8), 609-13.

Review

  1. Kramer HJ, Townsend RR, Griffin K, Flynn JT, Weiner DE, Rocco MV, Choi MJ, Weir MR, Chang TI, Agarwal R, Beddhu (2019). KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. American journal of kidney diseases, 73(4), 437-458.
  2. Kramer H, Tuttle KR, Leehey D, Luke A, Durazo-Arvizu R, Shoham D, Cooper R, Beddhu (2009). Obesity management in adults with CKD. American journal of kidney diseases, 53(1), 151-65.

Editorial

  1. Anand S, Beddhu (2025). BPROAD - End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes?. The New England journal of medicine, 392(12), 1230-1232.
  2. Mohan A, Beddhu (2024). Invisible Threat: How Air Pollution Fuels Primary Glomerular Disease. Kidney international reports, 9(9), 2591-2593.
  3. Katkam N, Beddhu (2024). Steps for Stopping Kidney Stones: Physical Activity Triumphant Over Genetics. American journal of kidney diseases, 84(4), 403-405.
  4. Koppe L, Beddhu S, Chauveau P, Kovesdy CP, Mafra D, Joshi S, Kalantar-Zadeh K, Fouque (2021). A call for a better understanding of the role of dietary amino acids and post-translational protein modifications of the microbiome in the progression of CKD. Nephrology, dialysis, transplantation, 36(8), 1357-1360.

Letter

  1. Beddhu S, Greene T, Boucher R, Cushman WC, Wei G, Cheung AK, Whelton PK, Chertow G (2018). Risk-benefit profile of intensive blood pressure treatment - Authors' reply. The lancet. Diabetes & endocrinology, 6(8), 602.

Other

  1. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, FIDELIO-DKD Investigator (2023). Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897. Diabetes care, 46(9), 1721.

Research Lab

News & Podcasts

News